海思科：获得创新药HSK45019片IND申请《受理通知书》

Core Viewpoint - The company announced that its subsidiary, Shanghai Hisun Shenno Pharmaceutical Technology Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the drug HSK45019 tablets, which pertains to the application for domestic production and clinical trial registration of the drug [2] Group 1 - The drug HSK45019 is under the process of clinical trial registration in China [2] - The acceptance notice indicates a step forward in the regulatory process for the company's pharmaceutical development [2]